Peripheral neuropathy and low dose cisplatin.
Five of 55 patients with metastatic carcinomas or unresectable primary carcinomas developed a peripheral neuropathy with "low dose" cisplatin therapy, consisting of 20 mg/m2 weekly. The neuropathy was primarily sensory, consisting of painful parasthesias and numbness in a "stocking glove" distribution. The cumulative dose at which neuropathy developed varied from 100 to 640 mg/m2. The symptoms and signs of neurologic dysfunction were minimally reversible despite discontinuation of the drug. Despite lower dose delivery of cisplatin, significant debilitating neurologic toxicity may occur.
Greenspan
A
A
Division of Medical Oncology, Lombardi Cancer Research Center, Georgetown University Medical Center, Washington, D.C. 20007.
Treat
J
J
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*
D002945:Cisplatin